Abbisko Signs an Exclusive License Agreement with Sperogenix to Develop ABSK021 for ALS and Other Rare Neurological Diseases in Greater China

Shots:

• Abbisko to receive upfront, milestones and royalties on net sales of the therapy & hold the rights for all other countries & indications. Sperogenix gets an exclusive right to develop, manufacture & commercialize ABSK021 in mainland China, Hong Kong SAR and Macao SAR for non-oncology rare neurological diseases
• Sperogenix will be responsible for the development of ABSK021 in ALS includes pre/ clinical studies, registration & commercialization of the product in the Sperogenix Territory
• ABSK021 is a selective CSF-1R antagonist. The P-Ib trial has initiated to evaluate safety, tolerability & PK of ABSK021 in China & the US while preliminary data demonstrate that ABSK021 was well tolerated

Click here to­ read full press release/ article | Ref: PR Newswire | Image: Abbisko